Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 96 Präparate · 6744 Quellenpassagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-086179 · Präparat HOS-083284
Medicinal Product Interactions – Ritonavir with Protease Inhibitors
Co-administered Dose of Co- Dose of Medicinal Product AUC Cmin
Medicinal Product administered NORVIR Assessed
Medicinal (mg)
Product
(mg)
Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold
1
Atazanavir ↑ 2 fold ↑ 3-7 fold
Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition.
Clinical trials confirmed the safety and efficacy of 300 mg atazanavir once daily with
ritonavir 100 mg once daily in treatment experienced patients. For further information,
physicians should refer to the SmPC for atazanavir.
Darunavir 600, single 100 q12h Darunavir ↑ 14 fold
Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition.
Darunavir must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses
higher than 100 mg twice daily have not been studied with darunavir. For further
information, refer to the SmPC for darunavir.
Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold
fold
Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of
CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic
effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice
daily with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily
10
have not been studied with fosamprenavir. For further information, physicians should refer
to the SmPC for fosamprenavir.
Indinavir 800 100 q12h Indinavir2 ↑ 178% ND
q12h
Ritonavir ↑ 72% ND
Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is
achieved with doses higher than 100 mg twice daily. In cases of co-administration of
ritonavir (100 mg twice daily) and indinavir (800 mg twice daily) caution is warranted as
the risk of nephrolithiasis may be increased.
Nelfinavir 1250 100 q12h Nelfinavir ↑ ND
q12h 20to39%
Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is
achieved with doses higher than 100 mg twice daily.
Tipranavir 500 200 q12h Tipranavir ↑ 11 fold ↑ 29 fold
q12h
Ritonavir ↓ 40% ND
Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition.
Tipranavir must be given with low dose ritonavir to ensure its therapeutic effect. Doses of
ritonavir less than 200 mg twice daily should not be used with tipranavir as they might alter
the efficacy of the combination. For further information, physicians should refer to the
SmPC for tipranavir.
ND: Not determined.
1. Based on cross-study comparison to 400 mg atazanavir once daily alone.
2. Based on cross-study comparison to 800 mg indinavir three times daily alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) tipranavir (HOS-086184) amprenavir (HOS-086183) indinavir (HOS-084518) protease (HOS-085623) atazanavir (HOS-086180) darunavir (HOS-086181) fosamprenavir (HOS-086182)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 03a194213ac89748c50cfb4b51554f8455df8df904ff2077009223828e61e82e · Zeichen 2655–7456 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 24
HOS-086344 · Präparat HOS-083284
Proton pump inhibitors and H2-receptor antagonists
Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce
concentrations for co-administered protease inhibitors. For specific information regarding the impact
of co-administration of acid reducing agents, refer to the SmPC of the co-administered protease
inhibitor. Based on interaction studies with the ritonavir boosted protease inhibitors
(lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not
significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of
exposure (about 6 - 18%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912) ranitidine (HOS-085660) protease (HOS-085623) lopinavir (HOS-086269) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 3c27321459baa7b0705afde806e8b539a0a25a4b47e2383e187fb6fd8f60bfb2 · Zeichen 60628–61278 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-086399 · Präparat HOS-083284
Co- Dose of Co- Dose of Medicinal Product AUC Cmin
administered administered NORVIR Assessed
Medicinal Medicinal Product (mg)
Product (mg)
Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold
1
Atazanavir ↑ 2 fold ↑ 3-7
fold
Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition. Clinical
trials confirmed the safety and efficacy of 300 mg atazanavir once daily with ritonavir 100 mg
once daily in treatment experienced patients. For further information, physicians should refer
to the SmPC for atazanavir.
Darunavir 600, single 100 q12h Darunavir ↑ 14 fold
Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition. Darunavir
must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses higher than
100 mg twice daily have not been studied with darunavir. For further information, refer to the
SmPC for darunavir.
Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold
fold
Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of
CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic
effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice daily
with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily have not
been studied with fosamprenavir. For further information, physicians should refer to the
SmPC for fosamprenavir.
Indinavir 800 q12h 100 q12h Indinavir2 ↑ 178% ND
Ritonavir ↑ 72% ND
Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved
with doses higher than 100 mg twice daily. In cases of co-administration of ritonavir (100 mg
twice daily) and indinavir (800 mg twice daily) caution is warranted as the risk of
nephrolithiasis may be increased.
Nelfinavir 1250 q12h 100 q12h Nelfinavir ↑ ND
20to39%
Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved
with doses higher than 100 mg twice daily.
Tipranavir 500 q12h 200 Tipranavir ↑ 11 fold ↑ 29 fold
q12h
Ritonavir ↓ 40% ND
Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition. Tipranavir
must be given with low dose ritonavir to ensure its therapeutic effect. Doses of ritonavir less
than 200 mg twice daily should not be used with tipranavir as they might alter the efficacy of
the combination. For further information, physicians should refer to the SmPC for tipranavir.
ND: Not determined.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tipranavir (HOS-086184) atazanavir (HOS-086180) darunavir (HOS-086181) fosamprenavir (HOS-086182) amprenavir (HOS-086183) indinavir (HOS-084518) nelfinavir (HOS-084520)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage d5308747ba178c6ebd0e34322c465d7122d5458d70aff134d17f324382a8fc16 · Zeichen 2732–7211 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-086400 · Präparat HOS-083284
1. Based on cross-study comparison to 400 mg atazanavir once daily alone.
2. Based on cross-study comparison to 800 mg indinavir three times daily alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) indinavir (HOS-084518)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 71fe7e533a1b113d7cbf463366af463ab42e4213a8966cd09c1bffbe648c857a · Zeichen 7235–7410 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56
HOS-086497 · Präparat HOS-083284
Proton pump inhibitors and H2-receptor antagonists
Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce
concentrations for co-administered protease inhibitors. For specific information regarding the impact
of co-administration of acid reducing agents, refer to the SmPC of the co-administered protease
inhibitor. Based on interaction studies with the ritonavir boosted protease inhibitors
(lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not
significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of
exposure (about 6 - 18%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912) ranitidine (HOS-085660) protease (HOS-085623) lopinavir (HOS-086269) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 4de66caff969925d9ad024610386f020326d8902794177858246b69263b12d3c · Zeichen 62968–63646 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.